Skip to main content

Table 1

From: Atazanavir is safe and efficacious in HBV and HCV co-infected patients: results of AI424138 (CASTLE)

Efficacy at Week 48

ATV/r N = 61

LPV/r N = 51

HIV RNA<50 c/mL, CVR (Non-Completer = Failure), n/N (%)

42/61 (69)

37/51 (73)

Mean CD4 Cell Count Change from Baseline (SE), cells/mm3

196 (26.1)

228 (21.7)